Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients

Sponsor
Grupo de Investigación y Divulgación Oncológica
Study ID
NCT01980472
Phase
PHASE2
Status
Unknown

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Eligibility Criteria

Sex
ALL
Age
70 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

A phase II Study of an adapted chemotherapy regimen plus bevacizumab in elderly non-small cell lung cancer patients selected by geriatric assessment

Key Dates

First listed
Nov 11, 2013
Start date
Aug 31, 2013
Status verified
Feb 2017
Primary completion
Jun 30, 2015
Completion
Aug 31, 2017

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: bevacizumab, carboplatin and paclitaxel
    bevacizumab, carboplatin and paclitaxel

Primary Outcome Measure

Rate of grade 3-4 neutropenia defined according to National Cancer Institute Common Terminology Criteria version 4.0 (NCI-CTC v4.0) [ Time Frame: participants will be followed for the duration of the study, around 3 years ]

Related Studies